A New Combination Therapy Utilizing Mitochondria-Targeting Small-Molecule Ligands and Clinical Inhibitors against Melanoma

with a clinical BRAF inhibitor (Vemurafenib, 0.2 μM) showed synergistic effects (CI = 0.67) against A375 cells. This new combined treatment significantly downregulates ATP production and glycolysis and induces acute senescence. The present study demonstrates an innovative and effective combination therapy strategy utilizing mitochondrion-targeting ligands and clinical inhibitors against melanoma.